Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Friday, 31 July 2020

CLINUVEL Corporate Update

Previous Next

Download PDF
 
 
Friday, 31 July 2020

Appendix 4C – quarterly

CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report and Activity Report for the period 01 April to 30 June 2020. All figures are rounded and reported in Australian dollars. Key Highlights: •  Cash receipts $10,403,000 over the quarter •  Net cash flow of $7,175,000 •  Cash and equivalents on hand increased […]

Download PDF
 
 
Thursday, 23 July 2020

Kommuniqué IV

Liebe Aktionäre, Freunde, Es stellt sich eine neue Welt dar, die darauf hinweist, dass das Virus nicht so leicht zu beseitigen sein wird. Waehrend wir es akzeptieren, einen Modus der Koexistenz zu finden, muessen wir für die mehr als 600.000 Menschen, die ihr Leben verloren haben und unzählige weitere, die von dieser Pandemie betroffen sind, […]

Download PDF
 
 
Wednesday, 22 July 2020

CLINUVEL Newsletter

Communiqué IV, 2020 – 22 July 2020 Dear shareholders, friends, As a new world presents itself indicating that the virus will not easily be eliminated as we are accepting to find a modus co-existentiae, albeit we need to pause for the more than 600,000 people who have lost their lives and countless more impacted by […]

Download PDF
 
 

Drug to be evaluated in patients with acute and systemic diseases Read more…

Download PDF
 
 

CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and conditions of issue that the following unquoted performance rights have lapsed and forfeited […] Download PDF

Download PDF
 
 

Download PDF with speaker notes

Download PDF
 
 
Thursday, 21 May 2020

Kommuniqué III

Liebe Aktionäre, Freunde, Die außergewöhnlichen Zeiten, in denen wir leben, haben alle Kontinente beeinflusst. Jedes verlorene Leben war eins zu viel. Ich kann unseren italienischen medizinischen Kollegen, Patienten und Familien, die mit der Tragödie kämpfen, nicht genug Empathie entgegenbringen. Das Virus hat alle Ecken der Welt befallen und Italien nicht verschont, insbesondere die Regionen Lombardei, […]

Download PDF
 
 
 
Tuesday, 19 May 2020

CLINUVEL Newsletter

Dear shareholders, friends, The extraordinary times in which we are living have affected all continents. Each life lost has been one too many. I cannot express enough empathy to our Italian medical colleagues, patients and families battling it out with the tragedy. The virus has affected all corners of the world and has not spared […]

Download PDF
 
 
Friday, 08 May 2020

Chair Letter to Shareholders

Fellow shareholders, In my March letter I wished all good health during uncertain times. It is now clear the extent of damage COVID-19 has caused and will cause for many years in the future. I want to again share my thoughts on the long-term view of CLINUVEL, and how the business was set up to […]

Download PDF
 
 
Wednesday, 06 May 2020

过度曝光

With thanks to Andrea Minoglio we are able to share a copy of his intimate EPP documentary Overexposed with Mandarin subtitles. What’s your life like when your skin, like an ultra-sensitive film, gets burned as soon as you expose it to the slightest amount of light? Using a series of interviews and stories, included that […]

Download PDF
 
 

EXECUTIVE SUMMARY CLINUVEL, FDA and global vitiligo experts attended FDA meeting on 29 April Type C Meeting followed up with further amendments to CUV104 clinical study protocol CLINUVEL PHARMACEUTICALS LTD today confirmed that it attended a Type C meeting on 29 April with the US Food and Drug Administration (FDA) and global clinical experts in […]

Download PDF
 
 
Tuesday, 28 April 2020

Appendix 4C

  EXECUTIVE SUMMARY ACTIVITY REPORT QUARTER ENDING 31 MARCH 2020  Key Activity Highlights: Continued supply of SCENESSE® in Europe  SCENESSE® launch in USA following Prior Authorization by US insurers Expansion of in-house R&D capabilities, Singaporean government provides financial incentives Throughout the quarter CLINUVEL has continued to focus on expanding its business activities during a time […]

Download PDF
 
Friday, 27 July 2018

CLINUVEL Newsletter - July 2018

27 July 2018 On 25 June 2018 CLINUVEL announced its New Drug Application (NDA) for SCENESSE® (afamelanotide 16mg) for adult erythropoietic protoporphyria (EPP) patients had been submitted to the US Food and Drug Administration (FDA). It …

Download PDF
 
Monday, 26 March 2018

CLINUVEL Newsletter - March 2018

26 March 2018 The erythropoietic protoporphyria (EPP) Expert Meeting in Vienna on 16 March has had quite an impact on our global teams working in the fields of photomedicine and melanocortins. The interest in SCENESSE® (afamelanotide …

Download PDF
 
Monday, 12 February 2018

CLINUVEL Newsletter - February 2018

12 February 2018 We started this year with limitless optimism and energy, and I attribute this to a foundation of internal changes made over the past 16 months. Our fascinating journey is marred with frequent need …

Download PDF
 
Wednesday, 10 January 2018

Chair Letter to Shareholders

11 January 2018 Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead. The Group will engage in many activities on several continents, and we …

Download PDF
 
Thursday, 07 December 2017

CLINUVEL Newsletter - December 2017

07 December 2017 The CLINUVEL team is looking with much optimism and energy to the start of 2018. I believe the year ahead is one where the Company will make great strides on various fronts: research, …

Download PDF